Global Therapeutic Nuclear Medicines Industry Growth and Trends Forecast to 2031

Summary

Radioactive material, called radiopharmaceuticals, can be used to treat certain conditions. This is called nuclear medicine therapy.

Therapeutic nuclear medicines are a pharmaceutical formulation that consists of radioactive substances (radioisotopes). Therapeutic nuclear medicines are intending for the treatment of cancer, metastatic bone pain and other diseases. The radioactive material of therapeutic nuclear medicines is capable of killing the cancerous tissue, reducing the size of a tumor and reducing pain.

According to APO Research, The global Therapeutic Nuclear Medicines market was estimated at US$ million in 2025 and is projected to reach a revised size of US$ million by 2031, witnessing a CAGR of xx% during the forecast period 2026-2031.

North American market for Therapeutic Nuclear Medicines is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2026 through 2031.

Asia-Pacific market for Therapeutic Nuclear Medicines is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2026 through 2031.

Europe market for Therapeutic Nuclear Medicines is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2026 through 2031.

The major global manufacturers of Therapeutic Nuclear Medicines include Novartis AG, Bayer, China Isotope & Radiation, Q BioMed, Curium Pharmaceuticals, Jubilant DraxImage, Dongcheng, Lantheus and Acrotech Biopharma., etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Therapeutic Nuclear Medicines, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Therapeutic Nuclear Medicines.

The Therapeutic Nuclear Medicines market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Therapeutic Nuclear Medicines market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

Key Companies & Market Share Insights

In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2020-2025. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses.

Therapeutic Nuclear Medicines Segment by Company

Novartis AG
Bayer
China Isotope & Radiation
Q BioMed
Curium Pharmaceuticals
Jubilant DraxImage
Dongcheng
Lantheus
Acrotech Biopharma.
Progenics Pharmaceuticals
International Isotopes

Therapeutic Nuclear Medicines Segment by Type

Radium-223
Lutetium-177
Iodine-131
Other

Therapeutic Nuclear Medicines Segment by Application

Thyroid
Bone Metastasis
Lymphoma
Other

Therapeutic Nuclear Medicines Segment by Region

North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Therapeutic Nuclear Medicines market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Therapeutic Nuclear Medicines and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Therapeutic Nuclear Medicines.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Therapeutic Nuclear Medicines manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Sales, revenue of Therapeutic Nuclear Medicines in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.
Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.
Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.
Chapter 13: Concluding Insights of the report.

Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.


1 Market Overview
1.1 Product Definition
1.2 Global Market Growth Prospects
1.2.1 Global Therapeutic Nuclear Medicines Market Size Estimates and Forecasts (2020-2031)
1.2.2 Global Therapeutic Nuclear Medicines Sales Estimates and Forecasts (2020-2031)
1.3 Therapeutic Nuclear Medicines Market by Type
1.3.1 Radium-223
1.3.2 Lutetium-177
1.3.3 Iodine-131
1.3.4 Other
1.4 Global Therapeutic Nuclear Medicines Market Size by Type
1.4.1 Global Therapeutic Nuclear Medicines Market Size Overview by Type (2020-2031)
1.4.2 Global Therapeutic Nuclear Medicines Historic Market Size Review by Type (2020-2025)
1.4.3 Global Therapeutic Nuclear Medicines Forecasted Market Size by Type (2026-2031)
1.5 Key Regions Market Size by Type
1.5.1 North America Therapeutic Nuclear Medicines Sales Breakdown by Type (2020-2025)
1.5.2 Europe Therapeutic Nuclear Medicines Sales Breakdown by Type (2020-2025)
1.5.3 Asia-Pacific Therapeutic Nuclear Medicines Sales Breakdown by Type (2020-2025)
1.5.4 South America Therapeutic Nuclear Medicines Sales Breakdown by Type (2020-2025)
1.5.5 Middle East and Africa Therapeutic Nuclear Medicines Sales Breakdown by Type (2020-2025)
2 Global Market Dynamics
2.1 Therapeutic Nuclear Medicines Industry Trends
2.2 Therapeutic Nuclear Medicines Industry Drivers
2.3 Therapeutic Nuclear Medicines Industry Opportunities and Challenges
2.4 Therapeutic Nuclear Medicines Industry Restraints
3 Market Competitive Landscape by Company
3.1 Global Top Players by Therapeutic Nuclear Medicines Revenue (2020-2025)
3.2 Global Top Players by Therapeutic Nuclear Medicines Sales (2020-2025)
3.3 Global Top Players by Therapeutic Nuclear Medicines Price (2020-2025)
3.4 Global Therapeutic Nuclear Medicines Industry Company Ranking, 2023 VS 2024 VS 2025
3.5 Global Therapeutic Nuclear Medicines Major Company Production Sites & Headquarters
3.6 Global Therapeutic Nuclear Medicines Company, Product Type & Application
3.7 Global Therapeutic Nuclear Medicines Company Establishment Date
3.8 Market Competitive Analysis
3.8.1 Global Therapeutic Nuclear Medicines Market CR5 and HHI
3.8.2 Global Top 5 and 10 Therapeutic Nuclear Medicines Players Market Share by Revenue in 2024
3.8.3 2023 Therapeutic Nuclear Medicines Tier 1, Tier 2, and Tier 3
4 Therapeutic Nuclear Medicines Regional Status and Outlook
4.1 Global Therapeutic Nuclear Medicines Market Size and CAGR by Region: 2020 VS 2024 VS 2031
4.2 Global Therapeutic Nuclear Medicines Historic Market Size by Region
4.2.1 Global Therapeutic Nuclear Medicines Sales in Volume by Region (2020-2025)
4.2.2 Global Therapeutic Nuclear Medicines Sales in Value by Region (2020-2025)
4.2.3 Global Therapeutic Nuclear Medicines Sales (Volume & Value), Price and Gross Margin (2020-2025)
4.3 Global Therapeutic Nuclear Medicines Forecasted Market Size by Region
4.3.1 Global Therapeutic Nuclear Medicines Sales in Volume by Region (2026-2031)
4.3.2 Global Therapeutic Nuclear Medicines Sales in Value by Region (2026-2031)
4.3.3 Global Therapeutic Nuclear Medicines Sales (Volume & Value), Price and Gross Margin (2026-2031)
5 Therapeutic Nuclear Medicines by Application
5.1 Therapeutic Nuclear Medicines Market by Application
5.1.1 Thyroid
5.1.2 Bone Metastasis
5.1.3 Lymphoma
5.1.4 Other
5.2 Global Therapeutic Nuclear Medicines Market Size by Application
5.2.1 Global Therapeutic Nuclear Medicines Market Size Overview by Application (2020-2031)
5.2.2 Global Therapeutic Nuclear Medicines Historic Market Size Review by Application (2020-2025)
5.2.3 Global Therapeutic Nuclear Medicines Forecasted Market Size by Application (2026-2031)
5.3 Key Regions Market Size by Application
5.3.1 North America Therapeutic Nuclear Medicines Sales Breakdown by Application (2020-2025)
5.3.2 Europe Therapeutic Nuclear Medicines Sales Breakdown by Application (2020-2025)
5.3.3 Asia-Pacific Therapeutic Nuclear Medicines Sales Breakdown by Application (2020-2025)
5.3.4 South America Therapeutic Nuclear Medicines Sales Breakdown by Application (2020-2025)
5.3.5 Middle East and Africa Therapeutic Nuclear Medicines Sales Breakdown by Application (2020-2025)
6 Company Profiles
6.1 Novartis AG
6.1.1 Novartis AG Comapny Information
6.1.2 Novartis AG Business Overview
6.1.3 Novartis AG Therapeutic Nuclear Medicines Sales, Revenue and Gross Margin (2020-2025)
6.1.4 Novartis AG Therapeutic Nuclear Medicines Product Portfolio
6.1.5 Novartis AG Recent Developments
6.2 Bayer
6.2.1 Bayer Comapny Information
6.2.2 Bayer Business Overview
6.2.3 Bayer Therapeutic Nuclear Medicines Sales, Revenue and Gross Margin (2020-2025)
6.2.4 Bayer Therapeutic Nuclear Medicines Product Portfolio
6.2.5 Bayer Recent Developments
6.3 China Isotope & Radiation
6.3.1 China Isotope & Radiation Comapny Information
6.3.2 China Isotope & Radiation Business Overview
6.3.3 China Isotope & Radiation Therapeutic Nuclear Medicines Sales, Revenue and Gross Margin (2020-2025)
6.3.4 China Isotope & Radiation Therapeutic Nuclear Medicines Product Portfolio
6.3.5 China Isotope & Radiation Recent Developments
6.4 Q BioMed
6.4.1 Q BioMed Comapny Information
6.4.2 Q BioMed Business Overview
6.4.3 Q BioMed Therapeutic Nuclear Medicines Sales, Revenue and Gross Margin (2020-2025)
6.4.4 Q BioMed Therapeutic Nuclear Medicines Product Portfolio
6.4.5 Q BioMed Recent Developments
6.5 Curium Pharmaceuticals
6.5.1 Curium Pharmaceuticals Comapny Information
6.5.2 Curium Pharmaceuticals Business Overview
6.5.3 Curium Pharmaceuticals Therapeutic Nuclear Medicines Sales, Revenue and Gross Margin (2020-2025)
6.5.4 Curium Pharmaceuticals Therapeutic Nuclear Medicines Product Portfolio
6.5.5 Curium Pharmaceuticals Recent Developments
6.6 Jubilant DraxImage
6.6.1 Jubilant DraxImage Comapny Information
6.6.2 Jubilant DraxImage Business Overview
6.6.3 Jubilant DraxImage Therapeutic Nuclear Medicines Sales, Revenue and Gross Margin (2020-2025)
6.6.4 Jubilant DraxImage Therapeutic Nuclear Medicines Product Portfolio
6.6.5 Jubilant DraxImage Recent Developments
6.7 Dongcheng
6.7.1 Dongcheng Comapny Information
6.7.2 Dongcheng Business Overview
6.7.3 Dongcheng Therapeutic Nuclear Medicines Sales, Revenue and Gross Margin (2020-2025)
6.7.4 Dongcheng Therapeutic Nuclear Medicines Product Portfolio
6.7.5 Dongcheng Recent Developments
6.8 Lantheus
6.8.1 Lantheus Comapny Information
6.8.2 Lantheus Business Overview
6.8.3 Lantheus Therapeutic Nuclear Medicines Sales, Revenue and Gross Margin (2020-2025)
6.8.4 Lantheus Therapeutic Nuclear Medicines Product Portfolio
6.8.5 Lantheus Recent Developments
6.9 Acrotech Biopharma.
6.9.1 Acrotech Biopharma. Comapny Information
6.9.2 Acrotech Biopharma. Business Overview
6.9.3 Acrotech Biopharma. Therapeutic Nuclear Medicines Sales, Revenue and Gross Margin (2020-2025)
6.9.4 Acrotech Biopharma. Therapeutic Nuclear Medicines Product Portfolio
6.9.5 Acrotech Biopharma. Recent Developments
6.10 Progenics Pharmaceuticals
6.10.1 Progenics Pharmaceuticals Comapny Information
6.10.2 Progenics Pharmaceuticals Business Overview
6.10.3 Progenics Pharmaceuticals Therapeutic Nuclear Medicines Sales, Revenue and Gross Margin (2020-2025)
6.10.4 Progenics Pharmaceuticals Therapeutic Nuclear Medicines Product Portfolio
6.10.5 Progenics Pharmaceuticals Recent Developments
6.11 International Isotopes
6.11.1 International Isotopes Comapny Information
6.11.2 International Isotopes Business Overview
6.11.3 International Isotopes Therapeutic Nuclear Medicines Sales, Revenue and Gross Margin (2020-2025)
6.11.4 International Isotopes Therapeutic Nuclear Medicines Product Portfolio
6.11.5 International Isotopes Recent Developments
7 North America by Country
7.1 North America Therapeutic Nuclear Medicines Sales by Country
7.1.1 North America Therapeutic Nuclear Medicines Sales Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
7.1.2 North America Therapeutic Nuclear Medicines Sales by Country (2020-2025)
7.1.3 North America Therapeutic Nuclear Medicines Sales Forecast by Country (2026-2031)
7.2 North America Therapeutic Nuclear Medicines Market Size by Country
7.2.1 North America Therapeutic Nuclear Medicines Market Size Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
7.2.2 North America Therapeutic Nuclear Medicines Market Size by Country (2020-2025)
7.2.3 North America Therapeutic Nuclear Medicines Market Size Forecast by Country (2026-2031)
8 Europe by Country
8.1 Europe Therapeutic Nuclear Medicines Sales by Country
8.1.1 Europe Therapeutic Nuclear Medicines Sales Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
8.1.2 Europe Therapeutic Nuclear Medicines Sales by Country (2020-2025)
8.1.3 Europe Therapeutic Nuclear Medicines Sales Forecast by Country (2026-2031)
8.2 Europe Therapeutic Nuclear Medicines Market Size by Country
8.2.1 Europe Therapeutic Nuclear Medicines Market Size Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
8.2.2 Europe Therapeutic Nuclear Medicines Market Size by Country (2020-2025)
8.2.3 Europe Therapeutic Nuclear Medicines Market Size Forecast by Country (2026-2031)
9 Asia-Pacific by Country
9.1 Asia-Pacific Therapeutic Nuclear Medicines Sales by Country
9.1.1 Asia-Pacific Therapeutic Nuclear Medicines Sales Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
9.1.2 Asia-Pacific Therapeutic Nuclear Medicines Sales by Country (2020-2025)
9.1.3 Asia-Pacific Therapeutic Nuclear Medicines Sales Forecast by Country (2026-2031)
9.2 Asia-Pacific Therapeutic Nuclear Medicines Market Size by Country
9.2.1 Asia-Pacific Therapeutic Nuclear Medicines Market Size Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
9.2.2 Asia-Pacific Therapeutic Nuclear Medicines Market Size by Country (2020-2025)
9.2.3 Asia-Pacific Therapeutic Nuclear Medicines Market Size Forecast by Country (2026-2031)
10 South America by Country
10.1 South America Therapeutic Nuclear Medicines Sales by Country
10.1.1 South America Therapeutic Nuclear Medicines Sales Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
10.1.2 South America Therapeutic Nuclear Medicines Sales by Country (2020-2025)
10.1.3 South America Therapeutic Nuclear Medicines Sales Forecast by Country (2026-2031)
10.2 South America Therapeutic Nuclear Medicines Market Size by Country
10.2.1 South America Therapeutic Nuclear Medicines Market Size Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
10.2.2 South America Therapeutic Nuclear Medicines Market Size by Country (2020-2025)
10.2.3 South America Therapeutic Nuclear Medicines Market Size Forecast by Country (2026-2031)
11 Middle East and Africa by Country
11.1 Middle East and Africa Therapeutic Nuclear Medicines Sales by Country
11.1.1 Middle East and Africa Therapeutic Nuclear Medicines Sales Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
11.1.2 Middle East and Africa Therapeutic Nuclear Medicines Sales by Country (2020-2025)
11.1.3 Middle East and Africa Therapeutic Nuclear Medicines Sales Forecast by Country (2026-2031)
11.2 Middle East and Africa Therapeutic Nuclear Medicines Market Size by Country
11.2.1 Middle East and Africa Therapeutic Nuclear Medicines Market Size Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
11.2.2 Middle East and Africa Therapeutic Nuclear Medicines Market Size by Country (2020-2025)
11.2.3 Middle East and Africa Therapeutic Nuclear Medicines Market Size Forecast by Country (2026-2031)
12 Value Chain and Sales Channels Analysis
12.1 Therapeutic Nuclear Medicines Value Chain Analysis
12.1.1 Therapeutic Nuclear Medicines Key Raw Materials
12.1.2 Key Raw Materials Price
12.1.3 Raw Materials Key Suppliers
12.1.4 Manufacturing Cost Structure
12.1.5 Therapeutic Nuclear Medicines Production Mode & Process
12.2 Therapeutic Nuclear Medicines Sales Channels Analysis
12.2.1 Direct Comparison with Distribution Share
12.2.2 Therapeutic Nuclear Medicines Distributors
12.2.3 Therapeutic Nuclear Medicines Customers
13 Concluding Insights
14 Appendix
14.1 Reasons for Doing This Study
14.2 Research Methodology
14.3 Research Process
14.4 Authors List of This Report
14.5 Data Source
14.5.1 Secondary Sources
14.5.2 Primary Sources
14.6 Disclaimer

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings